Home / Market News / $BMRN
benzinga Corporate Catalyst Impact 55/100 ● positive

Barclays Maintains Overweight on BioMarin Pharmaceutical, Raises Price Target to $114

Oct 14, 2026, 1:36 PM UTC · Primary ticker $BMRN

Barclays analyst Eliana Merle has reiterated an Overweight rating on BioMarin Pharmaceutical and increased its price target from $111 to $114. This indicates a continued positive outlook on the company's stock, suggesting potential for modest upside based on the analyst's valuation.

Barclays analyst Eliana Merle maintained an 'Overweight' rating on BioMarin Pharmaceutical and raised the price target from $111 to $114. This action signals continued confidence in the company's fundamentals and future performance. For traders, this represents a positive signal, potentially leading to short-term upward price movement as investors react to the analyst's updated valuation. While not a major catalyst like an earnings beat, a price target increase from a reputable firm can provide a modest boost and reinforce existing bullish sentiment, affecting BioMarin's stock positively in the near term.

$BMRN positive Analyst price target increase
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.